Nice hypothesis. Two issues.
Firstly, Wolgen has been as emphatic as humanly possible that with him in charge afamelanotide WILL NEVER be used for a cosmetic tan.
Secondly, Clinuvel over the last 5 years have reinterpreted the under promise over deliver mantra to under promise and then even with incredibly low expectations fail to meet them and set a new standard in under delivery.
How’s that vitiligo trial going? Wouldn’t mind an update.
Ann: Syd Capital Markets Briefing Presentation, page-73
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.37 |
Change
0.180(1.36%) |
Mkt cap ! $669.5M | |||
| Open | High | Low | Value | Volume |
| $13.19 | $13.59 | $13.13 | $1.181M | 88.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 606 | $13.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.51 | 282 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |